Key Points
- Maze Therapeutics CMO Harold Bernstein sold 16,142 shares at an average price of $27.61, generating proceeds of approximately $445,681 and reducing his ownership by 50%. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- MAZE shares opened at $27.18 and have declined 1.8%, while the company remains unprofitable after reporting a quarterly loss of $0.76 per share. Analysts expect a full-year loss of approximately $2.74 per share.
- Analyst sentiment remains mixed but leans positive: BTIG reaffirmed a Buy rating with a $46 target, contributing to a consensus Buy rating and average price target of $66, while other firms maintained or issued Sell ratings.
Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) CMO Harold Bernstein sold 16,142 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer owned 16,142 shares in the company, valued at $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Harold Bernstein also recently made the following trade(s):
- On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The stock was sold at an average price of $29.90, for a total transaction of $436,809.10.
Maze Therapeutics Trading Down 1.8%
Shares of MAZE stock opened at $27.18 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 18.31 and a quick ratio of 17.88. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21. Maze Therapeutics, Inc. has a 1 year low of $12.81 and a 1 year high of $53.65. The firm has a fifty day moving average price of $27.79 and a 200-day moving average price of $33.03.
Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting analysts' consensus estimates of ($0.76). As a group, equities analysts predict that Maze Therapeutics, Inc. will post -2.74 earnings per share for the current year.
Key Headlines Impacting Maze Therapeutics
Here are the key news stories impacting Maze Therapeutics this week:
- Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
- Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
- Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
- Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
- Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
- Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of MAZE. Royal Bank of Canada raised its holdings in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company's stock valued at $27,000 after acquiring an additional 363 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Maze Therapeutics in the fourth quarter valued at about $39,000. Ameritas Investment Partners Inc. boosted its stake in shares of Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after acquiring an additional 738 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Maze Therapeutics in the fourth quarter worth about $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Maze Therapeutics during the second quarter worth about $48,000.
Analyst Ratings Changes
Several research analysts have recently commented on MAZE shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen lowered shares of Maze Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Finally, BTIG Research restated a "buy" rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $66.00.
Get Our Latest Stock Analysis on Maze Therapeutics
About Maze Therapeutics
(
Get Free Report)
Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.
Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
